Gm6772 Inhibitors
Gm6772 inhibitors are a class of chemical compounds specifically designed to target and inhibit the function of the Gm6772 gene, which remains relatively uncharacterized but is thought to play a role in cellular processes such as gene regulation, intracellular signaling, and protein interactions. Like other genes of its kind, Gm6772 is likely involved in regulating transcriptional activities or modulating cellular responses to external stimuli. The exact functions of Gm6772 are not yet fully understood, but its potential involvement in fundamental biological processes makes it an important subject for research. Inhibiting Gm6772 provides an opportunity for scientists to investigate how this gene contributes to cellular dynamics and its influence on key pathways that maintain cellular homeostasis, gene expression, and cellular growth.
In research contexts, Gm6772 inhibitors are critical tools for exploring the molecular mechanisms in which Gm6772 may participate. By blocking Gm6772 activity, scientists can observe the downstream effects on cellular processes, such as changes in transcriptional regulation, disruptions in protein-protein interactions, or alterations in intracellular signaling networks. This inhibition allows researchers to investigate how Gm6772 affects cell cycle regulation, differentiation, and the cellular response to environmental stressors. Additionally, Gm6772 inhibitors offer insights into the interactions between Gm6772 and other regulatory molecules, helping to elucidate the broader networks that control gene expression and cellular stability. Through these studies, the use of Gm6772 inhibitors enhances our understanding of the roles that lesser-known genes play in regulating cellular behavior, shedding light on the complex regulatory systems that maintain proper cell function and adaptation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $39.00 $59.00 $104.00 $206.00 | 8 | |
Geldanamycin, an HSP90 inhibitor, directly impacts the heat shock protein 90 (HSP90) pathway. By inhibiting HSP90, it interferes with the chaperone function crucial for Lrrc74a folding, potentially leading to degradation or misfolding of the protein. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a PI3-kinase inhibitor, directly affects the phosphoinositide 3-kinase (PI3K) pathway. Inhibition of PI3K may indirectly impact Lrrc74a, as the PI3K pathway is implicated in various cellular processes, suggesting a potential regulatory link between PI3K signaling and the function of Lrrc74a. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132, a proteasome inhibitor, directly influences the ubiquitin-proteasome pathway. Inhibition of the proteasome may indirectly affect Lrrc74a, as the ubiquitin-proteasome pathway is implicated in the regulation of protein turnover, suggesting a potential regulatory link between proteasome activity and the stability of Lrrc74a. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib, a proteasome inhibitor, directly influences the ubiquitin-proteasome pathway. Inhibition of the proteasome may indirectly affect Lrrc74a, as the ubiquitin-proteasome pathway is implicated in the regulation of protein turnover, suggesting a potential regulatory link between proteasome activity and the stability of Lrrc74a. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib, an EGFR/HER2 inhibitor, directly affects the epidermal growth factor receptor (EGFR) pathway. Inhibition of EGFR may indirectly impact Lrrc74a, as EGFR pathways are implicated in various cellular processes, suggesting a potential regulatory link between EGFR signaling and the function of Lrrc74a. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, directly inhibits c-Jun N-terminal kinase (JNK), influencing the JNK signaling pathway. Inhibition of JNK may indirectly impact Lrrc74a, as JNK pathways are involved in diverse cellular processes, suggesting a potential regulatory link between JNK signaling and the function of Lrrc74a. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $33.00 $131.00 | 3 | |
PI-103, a dual PI3K/mTOR inhibitor, directly affects the PI3K/mTOR pathway. Inhibition of PI3K/mTOR may indirectly impact Lrrc74a, as the PI3K/mTOR pathway is implicated in various cellular processes, suggesting a potential regulatory link between PI3K/mTOR signaling and the function of Lrrc74a. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580, a p38 MAPK inhibitor, directly inhibits p38 MAPK, influencing the p38 MAPK pathway. Inhibition of p38 MAPK may indirectly impact Lrrc74a, as p38 MAPK pathways are implicated in various cellular processes, suggesting a potential regulatory link between p38 MAPK signaling and the function of Lrrc74a. | ||||||
17-AAG | 75747-14-7 | sc-200641 sc-200641A | 1 mg 5 mg | $67.00 $156.00 | 16 | |
17-AAG, an HSP90 inhibitor, directly impacts the heat shock protein 90 (HSP90) pathway. By inhibiting HSP90, it interferes with the chaperone function crucial for Lrrc74a folding, potentially leading to degradation or misfolding of the protein. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, an mTOR inhibitor, directly influences the mammalian target of rapamycin (mTOR) pathway. Inhibition of mTOR may indirectly impact Lrrc74a, as mTOR pathways are implicated in the regulation of various cellular processes, suggesting a potential regulatory link between mTOR signaling and the function of Lrrc74a. | ||||||